Given the well documented role of VEGF-C in driving metastasis, however, and the overlapping mechanisms used by DCs and tumor cells to access afferent lymphatic vessels [71–73], the safety of a pro-lymphangiogenic therapeutic approach in patients remains to be determined (Fig. 15). The gene discussed is VEGFC; the disease is neoplasm.